TY - JOUR
T1 - Serum and tissue CTACK/CCL27 chemokine levels in early mycosis fungoides may be correlated with disease-free survival following treatment with interferon alfa and psoralen plus ultraviolet A therapy
AU - Goteri, G.
AU - Rupoli, S.
AU - Campanati, A.
AU - Zizzi, A.
AU - Picardi, P.
AU - Cardelli, M.
AU - Giantomassi, F.
AU - Canafoglia, L.
AU - Marchegiani, F.
AU - Mozzicafreddo, G.
AU - Brandozzi, G.
AU - Stramazzotti, D.
AU - Ganzetti, G.
AU - Lisa, R.
AU - Simonetti, O.
AU - Offidani, A.
AU - Federici, I.
AU - Filosa, G.
AU - Leoni, P.
PY - 2012/5
Y1 - 2012/5
N2 - Background Neoplastic T-cell recruitment into the skin is a critical step in the pathogenesis of mycosis fungoides (MF), and the cutaneous T-cell attracting chemokine, CTACK/CCL27, might be involved. Objectives To investigate the clinical and prognostic significance of CTACK/CCL27 levels in patients with early-stage MF. Methods Serum samples and skin biopsy specimens were collected from 15 patients at the time of diagnosis and after the end of treatment with psoralen plus ultraviolet A/interferon alfa-2b combination therapy. Serum samples were also collected from 20 healthy donors as controls. CTACK/CCL27 serum levels were analysed by enzyme-linked immunosorbent assays. CTACK/CCL27 tissue expression was determined by immunohistochemistry on skin biopsy specimens taken at diagnosis and after therapy. Event-free survival was taken as the primary clinical outcome. Results In patients with MF at diagnosis, CTACK/CCL27 serum levels were not significantly different from healthy controls, whereas CTACK/CCL27 expression in the skin was increased in 87% of cases compared with normal controls. After therapy, all patients obtained a clinical complete remission, serum levels did not change significantly and tissue expression remained abnormal in 80% of patients, even if complete histological remission was recorded. Serum levels were not significantly different in cases with different intensity of cutaneous immunostaining. Eight patients experienced a relapse: the combination of high CTACK/CCL27 levels both in sera and skin increased the probability of experiencing an event at 51 months from 36% to 83%. Conclusions Our data seem to indicate that CTACK/CCL27 levels in skin and sera after therapy might be correlated with risk of recurrence.
AB - Background Neoplastic T-cell recruitment into the skin is a critical step in the pathogenesis of mycosis fungoides (MF), and the cutaneous T-cell attracting chemokine, CTACK/CCL27, might be involved. Objectives To investigate the clinical and prognostic significance of CTACK/CCL27 levels in patients with early-stage MF. Methods Serum samples and skin biopsy specimens were collected from 15 patients at the time of diagnosis and after the end of treatment with psoralen plus ultraviolet A/interferon alfa-2b combination therapy. Serum samples were also collected from 20 healthy donors as controls. CTACK/CCL27 serum levels were analysed by enzyme-linked immunosorbent assays. CTACK/CCL27 tissue expression was determined by immunohistochemistry on skin biopsy specimens taken at diagnosis and after therapy. Event-free survival was taken as the primary clinical outcome. Results In patients with MF at diagnosis, CTACK/CCL27 serum levels were not significantly different from healthy controls, whereas CTACK/CCL27 expression in the skin was increased in 87% of cases compared with normal controls. After therapy, all patients obtained a clinical complete remission, serum levels did not change significantly and tissue expression remained abnormal in 80% of patients, even if complete histological remission was recorded. Serum levels were not significantly different in cases with different intensity of cutaneous immunostaining. Eight patients experienced a relapse: the combination of high CTACK/CCL27 levels both in sera and skin increased the probability of experiencing an event at 51 months from 36% to 83%. Conclusions Our data seem to indicate that CTACK/CCL27 levels in skin and sera after therapy might be correlated with risk of recurrence.
UR - http://www.scopus.com/inward/record.url?scp=84860337443&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860337443&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2133.2012.10818.x
DO - 10.1111/j.1365-2133.2012.10818.x
M3 - Article
C2 - 22233400
AN - SCOPUS:84860337443
VL - 166
SP - 948
EP - 952
JO - British Journal of Dermatology
JF - British Journal of Dermatology
SN - 0007-0963
IS - 5
ER -